Lamivudin/Zidovudin Mylan

Lamivudine, the active ingredient in Lamivudin/Zidovudin Mylan, is a nucleoside reverse transcriptase inhibitor presented as an oral tablet for oral use. It is indicated for the treatment of HIV‑1 infection in both adults and children, often in combination with other antiretroviral agents.

GNH USA supplies Lamivudin/Zidovudin Mylan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product meets European Union quality standards and is manufactured under strict GMP conditions. It is distributed through regulated channels to ensure consistent availability.

Lamivudin/Zidovudin Mylan is used in antiretroviral therapy to control HIV‑1 replication.

- HIV‑1 infection (adults): reduces viral load and helps restore immune function. - HIV‑1 infection (children): improves growth parameters and decreases disease progression. - Prevention of mother‑to‑child transmission: lowers the risk of vertical HIV transmission when given to pregnant women.

The most frequently reported adverse reactions with lamivudine/zidovudine therapy involve hematologic and gastrointestinal systems.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Headache: transient cranial discomfort. - Fatigue: general tiredness. - Diarrhea: loose stools.

Serious or Rare Side Effects: - Severe anemia: marked reduction in red blood cells. - Lactic acidosis: buildup of lactate causing metabolic disturbance. - Neutropenia: significant drop in neutrophil count. - Hypersensitivity reactions: rash, fever, or organ involvement.

Before initiating lamivudine/zidovudine, clinicians should consider several safety measures to minimize risks.

- Baseline laboratory assessment: obtain CBC, liver and renal function tests prior to therapy. - Hematologic monitoring: perform regular CBC to detect anemia or neutropenia. - Liver function monitoring: assess transaminases periodically, especially in patients with hepatic disease. - Pregnancy considerations: evaluate risk‑benefit ratio, as data are limited. - Avoid monotherapy: use in combination regimens to prevent resistance development. - Store at room temperature: keep in original packaging, protect from moisture and direct sunlight.

Lamivudin/Zidovudin Mylan may interact with other medicines, altering efficacy or toxicity.

Major Interactions (Avoid): - Didanosine: concurrent use increases risk of pancreatitis. - Stavudine: combined therapy heightens mitochondrial toxicity. - Alcohol: may exacerbate liver injury. - Other NRTIs: additive bone‑marrow suppression.

Moderate Interactions (Monitor Closely): - Nevirapine: can raise lamivudine plasma levels. - Efavirenz: may affect zidovudine metabolism. - Rifampin: reduces zidovudine concentrations, potentially lowering antiviral effect.